IL152360A0 - Sustained release formulations - Google Patents
Sustained release formulationsInfo
- Publication number
- IL152360A0 IL152360A0 IL15236001A IL15236001A IL152360A0 IL 152360 A0 IL152360 A0 IL 152360A0 IL 15236001 A IL15236001 A IL 15236001A IL 15236001 A IL15236001 A IL 15236001A IL 152360 A0 IL152360 A0 IL 152360A0
- Authority
- IL
- Israel
- Prior art keywords
- sustained release
- release formulations
- crytallize
- polymeric
- viscosity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000013268 sustained release Methods 0.000 title abstract 2
- 239000012730 sustained-release form Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 239000012876 carrier material Substances 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 239000011344 liquid material Substances 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19820900P | 2000-04-19 | 2000-04-19 | |
PCT/US2001/012909 WO2001078683A2 (en) | 2000-04-19 | 2001-04-19 | Sustained release formulations comprising growth hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
IL152360A0 true IL152360A0 (en) | 2003-05-29 |
Family
ID=22732439
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15236001A IL152360A0 (en) | 2000-04-19 | 2001-04-19 | Sustained release formulations |
Country Status (11)
Country | Link |
---|---|
US (1) | US6992065B2 (xx) |
EP (1) | EP1274459B1 (xx) |
JP (1) | JP4361710B2 (xx) |
AT (1) | ATE309822T1 (xx) |
AU (2) | AU5911101A (xx) |
CA (1) | CA2406790C (xx) |
DE (1) | DE60115005T2 (xx) |
DK (1) | DK1274459T3 (xx) |
ES (1) | ES2253375T3 (xx) |
IL (1) | IL152360A0 (xx) |
WO (1) | WO2001078683A2 (xx) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1397155E (pt) * | 2001-06-21 | 2015-12-07 | Genentech Inc | Formulação de libertação sustentada |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
DE10242088A1 (de) * | 2002-09-11 | 2004-03-25 | Bayer Ag | Kontrolliertes Freisetzungssystem, welches Saccharoseacetatisobutyrat enthält |
SI2218448T1 (sl) | 2002-12-13 | 2016-01-29 | Durect Corporation | Sistem za oralno dajanje zdravila, ki obsega tekoči nosilec materialov z visoko viskoznostjo |
EP1578398A2 (en) * | 2002-12-19 | 2005-09-28 | ALZA Corporation | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
DE10312346A1 (de) * | 2003-03-20 | 2004-09-30 | Bayer Healthcare Ag | Kontrolliertes Freisetzungssystem |
EP1708734A4 (en) * | 2004-01-07 | 2009-06-17 | Trimeris Inc | PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS |
ES2378671T3 (es) * | 2004-09-17 | 2012-04-16 | Durect Corporation | Composición anestésica local prolongada que contiene SAIB |
CA2593112A1 (en) * | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
CA2596966A1 (en) * | 2005-02-03 | 2006-08-10 | Intarcia Therapeutics, Inc. | Implantable osmotic device for continuous delivery of suspension formulations |
DK3081215T3 (da) | 2005-05-23 | 2020-04-27 | Natural Alternatives Int Inc | Sammensætninger og fremgangsmåder til langvarig frigørelse af beta-alanin |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
ES2381631T3 (es) * | 2006-02-02 | 2012-05-30 | Synageva Biopharma Corp. | Péptidos inhibidores de la fusión del VIH con propiedades biológicas mejoradas |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
EP2117521B1 (en) | 2006-11-03 | 2012-06-27 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
US20080140106A1 (en) * | 2006-12-12 | 2008-06-12 | Kimberly-Clark Worldwide, Inc. | Enhanced cuff sealing for endotracheal tubes |
AU2007234612B2 (en) | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
JP2010523564A (ja) * | 2007-04-03 | 2010-07-15 | トリメリス,インコーポレーテッド | 抗ウイルス性ペプチド治療薬の送達のための新規製剤 |
PT2157967E (pt) | 2007-04-23 | 2013-04-03 | Intarcia Therapeutics Inc | Formulações de suspensões de péptidos insulinotrópicos e suas utilizações |
US7678764B2 (en) | 2007-06-29 | 2010-03-16 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein formulations for use at elevated temperatures |
EP2187932B1 (en) | 2007-08-07 | 2015-01-28 | DePuy Synthes Products, LLC | Protein formulations comprising gdf-5 in aqueous acidic solution |
JP2010540528A (ja) * | 2007-09-25 | 2010-12-24 | トリメリス,インコーポレーテッド | 治療的抗ウイルス性ペプチドの新規合成方法 |
US8114883B2 (en) | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
CA2706931C (en) * | 2007-12-06 | 2015-05-12 | Durect Corporation | Oral pharmaceutical dosage forms |
US20090181068A1 (en) | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
AU2009212367B2 (en) | 2008-02-08 | 2013-08-01 | Foresee Pharmaceuticals Co., Ltd. | Composition for sustained release delivery of proteins or peptides |
US8586103B2 (en) * | 2008-02-08 | 2013-11-19 | Foresee Pharmaceuticals, Llc | Non-polymeric compositions for controlled drug delivery |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
CA2720845A1 (en) | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
KR102148624B1 (ko) | 2009-09-28 | 2020-08-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
HUE038405T2 (hu) | 2009-12-15 | 2018-10-29 | Ascendis Pharma Endocrinology Div A/S | Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény |
EA026964B1 (ru) * | 2010-11-24 | 2017-06-30 | Дьюрект Корпорейшн | Биоразлагаемая композиция для доставки лекарственного средства (варианты) |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
ITMI20110445A1 (it) * | 2011-03-22 | 2012-09-23 | Lo Li Pharma Srl | Formulazione farmaceutica comprendente inositolo. |
CN102389571B (zh) * | 2011-11-22 | 2013-04-24 | 朱成钢 | 一种可体内注射的药物缓释栓剂 |
CN103127514B (zh) * | 2011-11-22 | 2014-07-02 | 朱成钢 | 一种可体内注射的药物缓释栓剂 |
AU2014233453A1 (en) | 2013-03-15 | 2015-10-01 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3988083A1 (en) | 2014-11-21 | 2022-04-27 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms |
KR20240042548A (ko) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
US11208736B2 (en) | 2017-09-25 | 2021-12-28 | Bolt Threads, Inc. | Methods of generating highly-crystalline recombinant spider silk protein fibers |
CN112566767A (zh) * | 2018-08-10 | 2021-03-26 | 保尔特纺织品公司 | 用于模制体的组合物 |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4016273A (en) * | 1975-07-16 | 1977-04-05 | American Cyanamid Company | Sustained release forms of certain oxazepines for parenteral administration |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
IL79681A (en) | 1985-08-12 | 1991-06-10 | Int Minerals & Chem Corp | Transition metal complexes of growth hormones and their prolonged release compositions |
WO1989003671A1 (en) | 1987-10-29 | 1989-05-05 | Dainippon Pharmaceutical Co., Ltd. | Sustained-release preparation |
US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US4975271A (en) | 1988-12-19 | 1990-12-04 | Vipont Pharmaceutical, Inc. | Muscosal delivery systems for treatment of periodontal disease |
US5324520A (en) | 1988-12-19 | 1994-06-28 | Vipont Pharmaceutical, Inc. | Intragingival delivery systems for treatment of periodontal disease |
US5776963A (en) * | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5133981A (en) | 1989-11-17 | 1992-07-28 | Atrix Laboratories, Inc. | Purification of benzophenanthridine alkaloids extracts from alkaloid extracts |
PT99345A (pt) | 1990-10-30 | 1992-09-30 | Alza Corp | Processo para a preparacao de sistemas apropriados para a libertacao de agentes terapeuticos |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
AU1757092A (en) * | 1991-03-28 | 1992-11-02 | Genentech Inc. | Stable growth hormone metal ion formulations |
US5252338A (en) | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5711968A (en) | 1994-07-25 | 1998-01-27 | Alkermes Controlled Therapeutics, Inc. | Composition and method for the controlled release of metal cation-stabilized interferon |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
ATE197550T1 (de) | 1993-02-23 | 2000-12-15 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6080429A (en) | 1993-10-25 | 2000-06-27 | Genentech, Inc. | Method for drying microspheres |
CA2143044C (en) | 1994-02-21 | 2005-04-12 | Yasutaka Igari | Matrix for sustained-release preparation |
US5556905A (en) | 1994-03-30 | 1996-09-17 | Reilly Industries, Inc. | Physically-modified degradable thermoplastic compositions |
EP0754032B1 (en) | 1994-04-08 | 2001-12-05 | Atrix Laboratories, Inc. | Liquid delivery compositions |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
CA2192773C (en) | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
US5792477A (en) | 1996-05-07 | 1998-08-11 | Alkermes Controlled Therapeutics, Inc. Ii | Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5981489A (en) | 1996-07-18 | 1999-11-09 | Alza Corporation | Non-aqueous protic peptide formulations |
US5851229A (en) | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
DK0839525T3 (da) | 1996-10-31 | 2004-11-29 | Takeda Pharmaceutical | Præparat med forlænget frigivelse |
WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
EP0949905B1 (en) | 1996-12-20 | 2001-07-18 | Alza Corporation | Injectable depot gel composition and method of preparing the composition |
US6051558A (en) | 1997-05-28 | 2000-04-18 | Southern Biosystems, Inc. | Compositions suitable for controlled release of the hormone GnRH and its analogs |
US6113947A (en) | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6191107B1 (en) | 1997-09-26 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Complex of human growth hormone and zinc |
US6039977A (en) | 1997-12-09 | 2000-03-21 | Alza Corporation | Pharmaceutical hydrogel formulations, and associated drug delivery devices and methods |
CN1173742C (zh) * | 1997-12-26 | 2004-11-03 | 山之内制药株式会社 | 缓释药物组合物 |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
CN1158068C (zh) | 1998-12-23 | 2004-07-21 | 安姆根有限公司 | 用于缓释蛋白质的多元醇/油悬浮剂 |
AU5025300A (en) | 1999-06-18 | 2001-01-09 | Southern Biosystems, Inc. | Compositions for controlled release of the hormone gnrh and its analogs |
US6245806B1 (en) | 1999-08-03 | 2001-06-12 | Merck & Co., Inc. | HIV integrase inhibitors |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
KR20030023878A (ko) * | 2000-06-26 | 2003-03-20 | 몬산토 테크놀로지 엘엘씨 | 소마토트로핀의 지속적인 방출을 위한 계면활성제 함유비수성 제제들 |
-
2001
- 2001-04-19 WO PCT/US2001/012909 patent/WO2001078683A2/en active IP Right Grant
- 2001-04-19 AU AU5911101A patent/AU5911101A/xx active Pending
- 2001-04-19 DK DK01932596T patent/DK1274459T3/da active
- 2001-04-19 JP JP2001575984A patent/JP4361710B2/ja not_active Expired - Fee Related
- 2001-04-19 IL IL15236001A patent/IL152360A0/xx not_active IP Right Cessation
- 2001-04-19 AU AU2001259111A patent/AU2001259111B2/en not_active Ceased
- 2001-04-19 ES ES01932596T patent/ES2253375T3/es not_active Expired - Lifetime
- 2001-04-19 CA CA002406790A patent/CA2406790C/en not_active Expired - Fee Related
- 2001-04-19 EP EP01932596A patent/EP1274459B1/en not_active Expired - Lifetime
- 2001-04-19 DE DE60115005T patent/DE60115005T2/de not_active Expired - Lifetime
- 2001-04-19 US US09/839,684 patent/US6992065B2/en not_active Expired - Fee Related
- 2001-04-19 AT AT01932596T patent/ATE309822T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2406790C (en) | 2009-07-07 |
JP4361710B2 (ja) | 2009-11-11 |
EP1274459B1 (en) | 2005-11-16 |
DE60115005D1 (de) | 2005-12-22 |
WO2001078683A3 (en) | 2002-05-30 |
EP1274459A2 (en) | 2003-01-15 |
US6992065B2 (en) | 2006-01-31 |
WO2001078683A2 (en) | 2001-10-25 |
AU2001259111B2 (en) | 2005-12-08 |
ES2253375T3 (es) | 2006-06-01 |
ATE309822T1 (de) | 2005-12-15 |
JP2004500423A (ja) | 2004-01-08 |
DE60115005T2 (de) | 2006-07-27 |
DK1274459T3 (da) | 2006-02-06 |
US20020001631A1 (en) | 2002-01-03 |
AU5911101A (en) | 2001-10-30 |
CA2406790A1 (en) | 2001-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5911101A (en) | Sustained release formulations | |
EP1017411A4 (en) | COMPOSITION PROVIDING REGULATED RELEASE OF HORMONE GNRH AND ITS ANALOGS | |
WO1999013913A3 (en) | High viscosity liquid controlled delivery system as a device | |
BG103489A (en) | Ziprasidon preparations | |
EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
MY122704A (en) | Stable hydrogenated lupulone antibacterial oral compositions | |
MY118835A (en) | Sustained release compositions and the process for their preparation | |
AP1414A (en) | Controlled release galantamine composition. | |
GEP20043203B (en) | EP4 Receptor Selective Agonists in the Treatment of Osteoporosis | |
HK1008774A1 (en) | A composition comprising an active agent dissolved in a glass-forming carrier and a process for the preparation thereof | |
MY125651A (en) | Eplerenone compositions | |
GEP20022709B (en) | Pharmaceutical Compositions Having Appetite Suppressant Activity | |
MY129356A (en) | Electrospun pharmaceutical compositions | |
GB2354545A (en) | Encapsulated breaker slurry compositions and methods of use | |
HUT67426A (en) | Pharmaceutical compositions containing nifedipine and process for the preparation thereof | |
WO1998029085A3 (en) | Skin product having continuing antimicrobial, antiviral, antiseptic, and healing properties | |
CA2259764A1 (en) | Pharmaceutical compositions containing mupirocin | |
NZ511085A (en) | Oral pharmaceutical compositions containing buprenorphin | |
HUP0203844A3 (en) | Compound with growth hormone releasing properties, pharmaceutical composition containing it and its use | |
GB9203299D0 (en) | Cosmetic and/or pharmaceutical compositions and methods for their use | |
BG105570A (en) | Pharmaceutical compositions for modified release insulin sensitiser | |
HK1036221A1 (en) | Topical composition containing human epidermal growth factor. | |
RO117500B1 (ro) | Compoziţie cosmetică | |
GEP20043313B (en) | Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |